Rosuvastatin 5 mg with LDL-C of 60 mg/dL: Appropriate Maintenance, Not Intensification
If you have a patient on rosuvastatin 5 mg with an LDL-C of 60 mg/dL, this represents adequate control for most risk categories and continuation is appropriate—however, for very high-risk patients (post-ACS, established ASCVD with diabetes, or extreme cardiovascular risk), you should intensify therapy to achieve LDL-C <55 mg/dL.
Risk-Stratified Approach
Very High-Risk Patients (Target LDL-C <55 mg/dL)
For patients with acute coronary syndrome, established atherosclerotic cardiovascular disease with additional high-risk features, or extreme cardiovascular risk, an LDL-C of 60 mg/dL does not meet guideline targets 1, 2, 1. The 2024 International Lipid Expert Panel and 2025 ACC/AHA guidelines explicitly recommend LDL-C <55 mg/dL (1.4 mmol/L) for these patients 1, 2.
Intensification strategy:
Add ezetimibe 10 mg to the rosuvastatin 5 mg. This combination produces greater LDL-C reductions (approximately 60-75% total reduction) compared to uptitrating rosuvastatin alone 3. The ACTE and I-ROSETTE trials demonstrated that adding ezetimibe to stable rosuvastatin 5 mg produced superior lipid improvements compared to doubling the rosuvastatin dose, with comparable or better tolerability 3.
If LDL-C remains ≥55 mg/dL after 4-6 weeks on rosuvastatin/ezetimibe combination, add a PCSK9 inhibitor 1.
High-Risk Patients (Target LDL-C <70 mg/dL)
For patients with established ASCVD but not meeting very high-risk criteria, an LDL-C of 60 mg/dL meets the guideline target 2, 4, 5. Continue rosuvastatin 5 mg without modification.
Moderate-Risk Patients (Target LDL-C <100 mg/dL)
An LDL-C of 60 mg/dL is well below target 5, 6, 7. Continue current therapy.
Special Populations Requiring Consideration
Asian Patients
Rosuvastatin 5 mg is the recommended starting dose for Asian patients due to increased plasma concentrations 8. If your patient is Asian with LDL-C 60 mg/dL on this dose, this represents appropriate therapy. Consider risks versus benefits before exceeding 20 mg daily in this population 8.
Patients with Diabetes or Metabolic Syndrome
For very high-risk patients with diabetes or metabolic disorders, consider that rosuvastatin 20 mg plus ezetimibe may be preferable to higher-dose rosuvastatin monotherapy to minimize new-onset diabetes risk while achieving aggressive LDL-C targets 1.
Severe Renal Impairment
In patients with CrCl <30 mL/min/1.73 m², rosuvastatin should not exceed 10 mg daily 8. If your patient has severe renal impairment on 5 mg with LDL-C 60 mg/dL, you can safely uptitrate to 10 mg if needed for very high-risk targets, but adding ezetimibe is preferable 8.
Efficacy Context of Rosuvastatin 5 mg
Rosuvastatin 5 mg produces approximately 39-45% LDL-C reduction from baseline 5, 9, 10, 11. This is significantly more effective than atorvastatin 10 mg (36%), simvastatin 20 mg (36%), or pravastatin 20 mg (27%) 10, 11. The dose also effectively raises HDL-C by 8-13% 11.
Common Pitfalls to Avoid
Don't uptitrate rosuvastatin alone when combination therapy is superior: The evidence clearly shows that adding ezetimibe to rosuvastatin 5 mg is more effective and better tolerated than doubling the rosuvastatin dose 3.
Don't assume all patients need the same target: Risk stratification is critical. A patient with primary prevention needs (moderate risk) achieving LDL-C 60 mg/dL is overtreated if you intensify further, while a post-MI patient at the same LDL-C level is undertreated.
Don't forget the 4-6 week reassessment window: After any lipid therapy adjustment, reassess LDL-C at 4-6 weeks to determine if further intensification is needed 1, 8.
Don't ignore statin-associated muscle symptoms: If the patient is on rosuvastatin 5 mg due to previous intolerance to higher doses, adding ezetimibe is the preferred intensification strategy rather than increasing the statin dose 3.